v3.26.1
Stockholders’ Equity (Tables)
 6 Months Ended
Jul. 03, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-Based Compensation
We allocated stock-based compensation for the 2017 Plan and the 2000 Employee Stock Purchase Plan (as amended and restated, the Amended ESPP) as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development$12,344 $14,143 $24,662 $23,665 
Selling, general and administrative20,219 21,928 36,951 38,336 
Total stock-based compensation$32,563 $36,071 $61,613 $62,001 
Stock-based compensation for each type of award under the 2017 Plan and the Amended ESPP were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Stock options$214 $671 $467 $1,731 
Restricted stock units31,644 34,626 58,703 57,728 
Performance-based restricted stock units— — — 241 
Employee stock purchase plan
705 774 2,443 2,301 
Total stock-based compensation$32,563 $36,071 $61,613 $62,001 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $55.31 per share for the 2026 TSR-based RSUs:
2026 TSR-based RSUs
Fair value of Exelixis common stock on grant date
$44.28 
Expected volatility
35.5%
Risk-free interest rate
3.4%
Dividend yield
—%